Nasdaq
$24.45▲ 0.31%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.84BShares out 1.200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
19- 9.28After-hours26.09.29 06:278-KKey event#●●●#●●●#●●●
Viking Therapeutics, Inc.
Viking Therapeutics, Inc. raised capital through a common stock offering and a convertible senior note offering on September 23, 2026. The company issued 7,857,143 shares at $35.00 per share for net proceeds of approximately $297.0 million, and $225 million in 2.00% convertible senior notes due 2032 for net proceeds of approximately $250.8 million. The proceeds will be used for the clinical development and commercialization of the VK2735 and VK3019 programs, as well as general corporate purposes.…more
$24.45+0.31%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.25Pre-market26.09.25 10:05filed424B5Offering
Viking Therapeutics, Inc.
Viking Therapeutics (VKTX) is raising $225 million through the issuance of 2.00% convertible senior notes due 2032, which includes an underwriters' over-allotment option of $33.75 million. The notes feature an initial conversion price of approximately $50.75 per share. Concurrently, the company is conducting a separate public offering of 7,857,143 shares of its common stock.…more
$24.45+0.31%vs prev closeView filingShare - 9.25Pre-market26.09.25 10:04filed424B5Offering
Viking Therapeutics, Inc.
Viking Therapeutics (VKTX) is conducting a public offering of 7,857,143 shares of common stock at $35.00 per share, raising approximately $275 million. Concurrently, the company is offering $225 million in 2.00% convertible senior notes due 2032. Underwriters have been granted a 30-day option to purchase an additional 1,178,571 shares.…more
$24.45+0.31%vs prev closeView filingShare
18 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14Pre-market26.10.14 20:09#●●●#●●●#●●●
Viking Therapeutics Initiates Phase 3 Clinical Program for Oral VK2735
Viking Therapeutics has officially launched the SUNRISE Phase 3 clinical program for its oral weight-loss drug candidate, VK2735. The trials will evaluate the efficacy and safety of the drug in adults with obesity and type 2 diabetes over a 68-week period.…more
$24.45+0.31%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.6Pre-market26.10.06 20:09
●●●●●●●● ●●●●● ●●●●●●
Viking Therapeutics has launched the second part of its maintenance study to evaluate various oral and subcutaneous dosing regimens for its obesity drug VK2735. The trial aims to assess the safety, tolerability, and efficacy of these regimens in maintaining weight loss achieved during the initial treatment phase.…more
$24.45+0.31%vs prev closeShareBenzinga - 9.24Regular26.09.25 00:32
●●●●●●●● ●●●●● ●●●●●●
Viking Therapeutics shares fell over 15% after the company announced an upsized public offering of 7.85 million shares and $225 million in convertible senior notes. While the capital is intended for clinical development, the dilution concerns have pressured the stock price.…more
$24.45+0.31%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report